alendronate has been researched along with Myasthenia Gravis in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate was stopped, and he was started on intravenous ibandronate injections given every 3 months." | 5.40 | Exacerbation of myasthenia gravis by alendronate. ( Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F, 2014) |
| "Alendronate was stopped, and he was started on intravenous ibandronate injections given every 3 months." | 1.40 | Exacerbation of myasthenia gravis by alendronate. ( Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lv, F | 1 |
| Guan, Y | 1 |
| Ma, D | 1 |
| Xu, X | 1 |
| Song, Y | 1 |
| Li, L | 1 |
| Jiang, Y | 1 |
| Wang, O | 1 |
| Xia, W | 1 |
| Xing, X | 1 |
| Li, M | 1 |
| Kesikburun, S | 1 |
| Güzelküçük, U | 1 |
| Alay, S | 1 |
| Yavuz, F | 1 |
| Tan, AK | 1 |
2 other studies available for alendronate and Myasthenia Gravis
| Article | Year |
|---|---|
Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Topics: Aged; Alendronate; Asian People; Bone and Bones; Bone Density; Bone Remodeling; Drug Therapy, Combin | 2018 |
Exacerbation of myasthenia gravis by alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Ibandronic A | 2014 |